Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
- Carole Paley
- Martin Griesshammer
- Francesca Palandri
- Mathias Hänel
- Carmen Garcia-Hernandez
- Tomasz Sacha
- Bruno Martino
- Daniela Damiani
- Andrey Zaritskey
- Pilar Giraldo
- Francesco Mannelli
- Catherine Bouard
- Philipp le Coutre
- Giuseppe A. Palumbo
- Alessandro M. Vannucchi
- Renato Tavares
- Haifa Kathrin Al-Ali
- Pia Raanani
- Ranjan Tiwari
- Anna Marina Liberati
- Vikas Gupta
- Lynda Foltz
DOIAbstract
SummaryRuxolitinib is a potent Janus kinase (JAK) 1/JAK2 inhibitor approved for the treatment of myelofibrosis (MF). Ruxolitinib was assessed in JUMP, a large (N = 2233), phase 3b, expanded‐access study in MF in countries without access to ruxolitinib outside a clinical trial, which included patients with low platelet counts (<100 × 109/l) and patients without splenomegaly – populations that have not been extensively studied. The most common adverse events (AEs) were anaemia and thrombocytopenia, but they rarely led to discontinuation (overall, 5·4%; low‐platelet cohort, 12·3%). As expected, rates of worsening thrombocytopenia were higher in the low‐platelet cohort (all grades, 73·2% vs. 53·5% overall); rates of anaemia were similar (all gr...
Add to ORKG